-
Devasthale,P., Wang,Y., Wang,W., Fevig,J., Feng,J., Wang,A., Harrity,T., Egan,D., Morgan,N., Cap,M., Fura,A., Klei,H.E., Kish,K., Weigelt,C., Sun,L., Levesque,P., Moulin,F., Li,Y.X., Zahler,R., Kirby,M.S. and Hamann,L.G.
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]py ridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)
J Med Chem (2013) 56, 7343-7357. PubMed Europe PubMed DOI
2013
